Íæż½ã½ã

  • By clicking "OK" or continuing to use this site, you agree that we may collect and use your personal data and set cookies to improve your experience and customise advertising. To see how, and to learn how to control cookies, please read our Privacy Policy and Cookie Policy.
OK
Advertisement
In the last 4 hours
GlobeNewswire (Press Release)15:12
In the last 6 hours
Pharmaceutical Technology12:08
Earlier today
Pharmacy Times09:16
The Fresno Bee08:25
The Motley Fool06:53
British Medical Journal02:00
Yesterday
Boston Globe20:44 18-Sep-24
Seeking Alpha20:11 18-Sep-24
Benzinga15:46 18-Sep-24
Yahoo! US15:16 18-Sep-24
The Washington Times14:01 18-Sep-24
BNN Bloomberg13:31 18-Sep-24
Yahoo! US11:41 18-Sep-24
The Motley Fool10:08 18-Sep-24
World Economic Forum09:55 18-Sep-24
FierceBiotech09:28 18-Sep-24
Mercury News08:49 18-Sep-24
ENDPOINTS08:11 18-Sep-24
Business Wire (Press Release)08:01 18-Sep-24
pharmaphorum05:05 18-Sep-24
In the last 7 days
The Economic Times20:53 17-Sep-24
Yahoo! US19:20 17-Sep-24
Forbes17:49 17-Sep-24
Yahoo! US17:38 17-Sep-24
JD Supra16:42 17-Sep-24
Quartz16:04 17-Sep-24
PharmTech.com14:56 17-Sep-24
Yahoo! US14:25 17-Sep-24
Fortune14:16 17-Sep-24
Common Dreams14:12 17-Sep-24
Press-Telegram, California14:03 17-Sep-24
Orange County Register14:00 17-Sep-24
Bloomberg Law13:29 17-Sep-24
Public Citizen12:14 17-Sep-24
Public Citizen12:14 17-Sep-24
euronews03:56 17-Sep-24
Common Dreams18:12 16-Sep-24
FierceBiotech09:49 16-Sep-24
The Motley Fool06:14 15-Sep-24
The Motley Fool05:37 14-Sep-24
Medpage Today01:35 14-Sep-24
TCTMD16:15 13-Sep-24
Bloomberg Law15:31 13-Sep-24
Mint14:20 13-Sep-24
BNN Bloomberg13:39 13-Sep-24
The Mirror13:36 13-Sep-24
BioWorld12:56 13-Sep-24
Irish Examiner12:02 13-Sep-24
Zacks09:01 13-Sep-24
BNN Bloomberg08:05 13-Sep-24
Society for Endocrinology05:05 13-Sep-24
Pulitzer Center17:47 12-Sep-24
Pulitzer Center17:47 12-Sep-24
Invezz16:09 12-Sep-24
Fox News14:51 12-Sep-24
Zacks14:31 12-Sep-24
Zacks12:08 12-Sep-24
The Motley Fool06:05 12-Sep-24
Yahoo! US05:33 12-Sep-24
In the last month
PR Newswire (Press Release)18:13 11-Sep-24
Pulitzer Center16:11 11-Sep-24
UPI15:40 11-Sep-24
Study Finds15:24 11-Sep-24
TurnTo23.com, California15:23 11-Sep-24
ENDPOINTS15:03 11-Sep-24
24/7 Wall St.14:49 11-Sep-24
Quartz13:35 11-Sep-24
Pulitzer Center12:19 11-Sep-24
Pulitzer Center11:39 11-Sep-24
Pulitzer Center11:39 11-Sep-24
FierceBiotech11:10 11-Sep-24
Fortune10:55 11-Sep-24
Quartz10:42 11-Sep-24
Pharmaceutical Technology09:49 11-Sep-24
Benzinga09:26 11-Sep-24
Forbes08:20 11-Sep-24
ENDPOINTS07:14 11-Sep-24
DD News07:11 11-Sep-24
pharmaphorum06:48 11-Sep-24
HealthDay06:02 11-Sep-24
Benzinga04:21 11-Sep-24
Business Insider02:25 11-Sep-24
News-Medical.Net22:39 10-Sep-24
BNN Bloomberg20:34 10-Sep-24
NECN, New England18:39 10-Sep-24
ABC News18:12 10-Sep-24
Yahoo! UK & Ireland14:48 10-Sep-24
Quartz13:39 10-Sep-24
FiercePharma12:30 10-Sep-24
GlobeNewswire (Press Release)09:02 10-Sep-24
Business Wire (Press Release)08:09 10-Sep-24
Seeking Alpha05:50 10-Sep-24
Korea Biomedical Review01:02 10-Sep-24
The Good Men Project19:34 9-Sep-24
Law36016:55 9-Sep-24
BNN Bloomberg13:13 9-Sep-24
TipRanks11:29 9-Sep-24
TipRanks11:29 9-Sep-24
GlobeNewswire (Press Release)10:12 9-Sep-24
PR Newswire (Press Release)08:54 9-Sep-24
Business Wire (Press Release)02:19 9-Sep-24
Bursa.ro17:05 8-Sep-24
The Independent12:18 6-Sep-24
Nasdaq12:12 6-Sep-24
The Times of India03:57 6-Sep-24
PR Newswire (Press Release)17:47 5-Sep-24
PharmTech.com15:20 5-Sep-24
People14:51 5-Sep-24
What's Trending13:38 5-Sep-24
Benzinga13:26 5-Sep-24
The Motley Fool08:24 5-Sep-24
EasternEye07:06 5-Sep-24
Yahoo! UK & Ireland05:13 5-Sep-24
Labiotech04:16 5-Sep-24
Korea Biomedical Review00:35 5-Sep-24
view more headlines
19 Sep 15:12

About our Novo Nordisk news

Latest news on Novo Nordisk, a global healthcare company focused on diabetes care, obesity treatment, and other serious chronic diseases. Get updates on Novo Nordisk's products, research, financial performance, and stock price.

Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark. Founded in 1923, the company has grown to become a global leader in diabetes care, with a strong presence in the fields of hemophilia, growth hormone therapy, and obesity treatment. Novo Nordisk's key products include insulin analogs like Tresiba and Levemir, GLP-1 receptor agonists such as Victoza and Ozempic, and obesity drugs like Saxenda and Wegovy.

Stay informed about the latest developments in Novo Nordisk's research and development pipeline, including updates on clinical trials, regulatory approvals, and new product launches. Our feed covers the company's ongoing efforts to innovate and improve treatments for diabetes, obesity, and other metabolic disorders, such as the development of oral semaglutide and the exploration of novel drug targets.

In addition to product news, our Novo Nordisk feed keeps you updated on the company's financial performance, including quarterly earnings reports, sales figures, and market share data. We also cover key events and announcements that may impact Novo Nordisk's stock price (NYSE: NVO), such as strategic partnerships, acquisitions, and leadership changes.

Beyond the business aspects, our feed highlights Novo Nordisk's commitment to corporate social responsibility and sustainability. From initiatives to improve access to diabetes care in developing countries to efforts to reduce the company's environmental footprint, we provide a comprehensive view of Novo Nordisk's impact on global health and society.

As the prevalence of diabetes and obesity continues to rise worldwide, Novo Nordisk plays a crucial role in addressing these global health challenges. Our Íæż½ã½ã feed on Novo Nordisk brings you the most relevant and up-to-date information from reliable sources, helping you stay informed about this innovative and influential healthcare company.


Publication filters

Headline Density

Sorry, no headlines or news topics were found. Please try different keywords.